Hub

Cross-border healthcare strategy hub

Cross-border strategy requires more than country interest. It requires understanding regulation, payment, evidence, channels, procurement, and institutional trust.

Glossary Source methodology Sitemap

1Start with structureRead the overview before specialized pages.

2Use comparisons carefullySimilar words often describe different institutions.

3Check maintenance markersRegulatory and payment pages change more quickly.

4Follow internal linksThe site is designed as a reference graph.

Core pages

Recommended starting points

These pages define the cluster and point to more specialized pages as the site build expands.

Market entry

U.S. companies entering China

Approval, evidence, pricing, procurement, and partner strategy.

Market entry

Chinese companies entering the U.S.

FDA, payment, evidence, sales, service, and trust.

Collaboration

Cross-border partnerships

Academic, commercial, and institutional partnership structures.

Cluster index

Current foundation links

Start HereReader orientation GlossaryTerms Source MethodologySources SitemapFull index 2012 ArchiveHistorical material Editorial StandardsMaintenance rules

U.S. system foundation layer

U.S. healthcare system, payer, provider, and access pages

These pages explain the fragmented U.S. payer and provider system for readers comparing it with China.

U.S.-China comparison layer

Researched U.S.-China comparison pages

These pages compare the institutional mechanisms that drive access, payment, provider behavior, technology adoption, and regulation in the two systems.

U.S. vs. China Healthcare Systemsystem architecture comparison U.S. vs. China Health Insuranceinsurance architecture and financial protection comparison U.S. vs. China Hospitalshospital role, ownership, hierarchy, and patient behavior U.S. vs. China Primary Caregatekeeping, community care, and first-contact access U.S. vs. China Rural Healthcarerural access with different institutional causes U.S. vs. China Urban Healthcareurban concentration and navigation problem U.S. vs. China Public Healthpublic-health administration and state capacity U.S. vs. China Aging and Healthcareaging pressure, family structure, and financing U.S. vs. China Long-Term Carelong-term care financing and delivery U.S. vs. China Physician Workforcetraining, compensation, status, and practice environment U.S. vs. China Nursing Workforcenursing supply, role, and staffing context U.S. vs. China Medical Educationmedical training, licensing, and career pathway U.S. vs. China Hospital PaymentDRGs, FFS, budgets, payer contracts, and incentives U.S. vs. China Drug PricingPBMs, Medicare, NRDL, VBP, and negotiation U.S. vs. China Medical Device Pricinghospital purchasing, GPOs, VBP, and value analysis U.S. vs. China Reimbursementpayment pathways for products and services U.S. vs. China Health Technologyadoption environment for digital health and medtech U.S. vs. China Telehealthtelehealth regulation, payment, and adoption patterns U.S. vs. China Healthcare Data PrivacyHIPAA versus PIPL and data-security context U.S. vs. China AI Governance in Healthcaremedical AI regulation, data governance, and adoption

Regulatory strategy layer

Regulation, approval, trials, and postmarket governance pages

These pages analyze FDA and NMPA pathways, drug and device approval, clinical trials, real-world evidence, postmarket surveillance, software, cybersecurity, and regulatory localization.

FDA vs. NMPAregulator mandate and institutional operating model Drug Approval in the United States and Chinadrug evidence, review, and market-access sequencing Medical Device Approval in the United States and Chinaclassification, risk, evidence, and route-to-market Diagnostics Approval in the United States and ChinaIVD, laboratory, and clinical-use pathway Digital Therapeutics Regulation in the U.S. and Chinasoftware claims, clinical evidence, and payment uncertainty AI Medical Device Regulation in the U.S. and ChinaAI-enabled SaMD, lifecycle change, validation, and safety Clinical Trials in the U.S. and Chinatrial authorization, sites, ethics, and evidence transferability Human Subjects Research in Chinaethics, consent, institution, and participant protection Good Clinical Practice in Chinaclinical trial quality system Ethics Committees in Chinainstitutional research gatekeeper Postmarket Surveillance in Chinapost-approval safety and lifecycle control Pharmacovigilance in Chinadrug safety monitoring and risk management Medical Device Adverse Event Reporting in Chinadevice safety signal and corrective action Real-World Evidence in Chinaevidence beyond traditional trials Accelerated Approval Pathways in Chinapriority, breakthrough, conditional, and urgent-need review Breakthrough Medical Device Pathways in the U.S. and Chinaexpedited medtech review and market implications Companion Diagnostics in the U.S. and Chinadrug-diagnostic co-development and access Software as a Medical Device in Chinasoftware classification, registration, and lifecycle control Cybersecurity for Medical Devices in Chinadevice safety, data security, and network risk Regulatory Localization in Chinamarket-entry playbook for adapting global regulatory strategy

Biopharma strategy layer

Biopharma, supply-chain, licensing, and commercialization pages

These pages analyze U.S.-China biopharma strategy through asset evidence, manufacturing, APIs, generics, biologics, oncology, rare disease, CROs, CDMOs, licensing, IP, investment, trials, and payer evidence.

U.S.-China Biopharma Strategyportfolio, evidence, regulatory, and access sequencing Pharmaceutical Supply Chains and ChinaAPI, intermediate, finished-dose, resilience, and geopolitical exposure Active Pharmaceutical Ingredients in ChinaAPI manufacturing role and supply-chain dependency Generic Drugs in Chinaquality consistency, procurement, and price compression Innovative Drug Development in Chinadomestic innovation, global licensing, and evidence maturity Biologics in Chinacomplex manufacturing, clinical differentiation, and access Biosimilars in Chinacomparability, competition, and access economics Oncology Drugs in Chinahigh-demand therapeutic area with reimbursement and testing constraints Rare Disease Drugs in Chinaorphan-drug approval, diagnosis, reimbursement, and patient identification Cell and Gene Therapy in Chinaadvanced therapy regulation, manufacturing, delivery, and payment Contract Research Organizations in Chinatrial execution, regulatory support, and development infrastructure CDMOs in Chinadevelopment, manufacturing, quality, and supply-chain partnership Cross-Border Licensing in Life Sciencesrights, evidence, territory, economics, and control U.S.-China Biotech Investmentcapital, policy risk, valuation, and strategic optionality Intellectual Property in U.S.-China Life Sciencespatent protection, trade secrets, licensing trust, and enforcement Technology Transfer in U.S.-China Life Sciencesknow-how movement, control, policy sensitivity, and execution risk Clinical Trial Recruitment in Chinasite scale, disease burden, competition, and data quality China in Global Clinical Trialsglobal development network participation Pharma Commercialization in Chinaapproval, NRDL, hospital access, pricing, and medical affairs playbook Payer Evidence for Drugs in Chinareimbursement value, budget impact, and affordability evidence

Medtech strategy layer

Medtech, diagnostics, laboratory, procurement, and channel pages

These pages analyze China medtech strategy through device category, NMPA registration, hospital procurement, diagnostics, labs, service support, VBP exposure, and distributor control.

U.S.-China Medtech Strategyapproval, procurement, clinical workflow, and service infrastructure Medical Devices in Chinadevice-market architecture and regulatory-commercial pathway High-Value Medical Consumables in Chinaprocedure-linked consumables and procurement pressure Imaging Equipment in Chinacapital equipment, hospital capability, procurement, and localization In Vitro Diagnostics in ChinaIVD regulation, laboratory workflow, procurement, and clinical actionability Companion Diagnostics in Chinaoncology testing, therapy linkage, and access bottleneck Genetic Testing in Chinaclinical genetics, data governance, and laboratory access Laboratory Medicine in Chinahospital labs, reference labs, test economics, and quality systems Reference Laboratories in Chinathird-party testing infrastructure and specialized diagnostics Hospital Laboratories in Chinahospital-owned diagnostic infrastructure and procurement pathway Point-of-Care Testing in Chinadecentralized diagnostics and workflow tradeoffs Digital Pathology in Chinascanner workflow, pathology capacity, AI adjacency, and hospital adoption Cardiology Devices in Chinahigh-volume cardiovascular device market and procurement pressure Orthopedic Devices in Chinaimplant market, surgeon preference, and VBP implications Surgical Robots in Chinacapital robotics, local competition, procedure economics, and hospital prestige Dental Devices in Chinaconsumer-pay dentistry and device/service market Ophthalmology Devices in Chinaprocedure volume, diagnostics, implants, and private-public service mix Medical Device Procurement in Chinapurchasing pathway separate from registration Medical Device Service and Maintenance in Chinaafter-sales service as adoption risk and hospital operational issue Medical Device Distributor Models in Chinachannel strategy, control, compliance, and end-user visibility

Digital health strategy layer

Digital health, AI, EHR, interoperability, data, and cybersecurity pages

These pages analyze digital-health adoption through payment, workflow, data governance, AI validation, interoperability, cybersecurity, and U.S.-China institutional differences.

Digital Health in the U.S. and Chinaplatforms, payment, data governance, and provider workflow Internet Hospitals in ChinaChina-specific online care institution Telehealth in Chinainternet hospitals, online follow-up, platforms, and policy control Telehealth in the United Statespayer coverage, state licensure, Medicare policy, and provider workflow AI in Healthcare in Chinahospital pilots, data governance, AI-device regulation, and state industrial strategy AI in Healthcare in the United StatesFDA, workflow, liability, payer use, and provider adoption AI Medical Imaging in Chinaimaging AI as regulated device and workflow tool Clinical Decision Support in ChinaCDS software, hospital workflow, and regulatory boundary Hospital AI Adoption in Chinahospital incentives, pilots, procurement, and workflow integration Health Data Infrastructure in Chinahospital data, regional platforms, governance, and secondary use Electronic Health Records in Chinahospital-centered digitization and fragmentation Electronic Health Records in the United Statescertification, interoperability, burden, and market concentration Healthcare Interoperability in the U.S. and Chinadata liquidity under different institutional constraints Patient Portals in the U.S. and Chinapatient access, engagement, and platform mediation Mobile Health in Chinaplatform economy, hospital linkage, and public-health use Wearable Health Technology in Chinaconsumer devices, clinical monitoring, data rights, and validation Remote Patient Monitoring in the U.S. and Chinareimbursement versus platform and hospital implementation Digital Therapeutics in the U.S. and Chinaregulated claim, clinical evidence, prescription pathway, and payment Cross-Border Health Data in U.S.-China Healthcareprivacy, localization, research transfer, cybersecurity, and geopolitical risk Healthcare Cybersecurity in the U.S. and Chinaclinical continuity, data protection, connected devices, and institutional risk

Market entry playbook layer

China healthcare market-entry and commercialization pages

These pages analyze market entry through partner selection, procurement, pricing, KOLs, pilots, regulatory sequencing, diligence, reimbursement evidence, data compliance, and execution mistakes.

U.S. Healthcare Companies Entering Chinacanonical U.S.-to-China market entry playbook China Market Entry Strategy for Healthcare Companiesgeneral market-entry framework across product types China Market Access for Medtechmedtech route from approval to hospital adoption China Market Access for Biopharmabiopharma route from approval to reimbursement and clinical use China Hospital Procurement Strategypractical procurement pathway and account strategy Partner Selection in China Healthcaredecision matrix for distributors, JVs, licensing, and direct presence Healthcare Distributors in Chinadistributor role and channel risk Healthcare Joint Ventures in ChinaJV structure, rationale, and risk Academic Medical Partnerships with Chinapartnership model, benefits, and governance risks Localization Strategy for Healthcare Companies in Chinaproduct, evidence, manufacturing, service, and messaging localization Pricing Strategy for Healthcare Products in Chinaprice, VBP, NRDL, tendering, and hospital economics Evidence Strategy for China Market Accessclinical, economic, and local evidence needs KOL Strategy in Chinese HealthcareKOLs, academic hospitals, and specialty societies Tendering in Chinese Healthcaretendering process and procurement implications Hospital Pilot Strategy in Chinahow pilots work and why they fail to convert Regulatory Sequencing for China Market Entrysequence NMPA, evidence, partner, reimbursement, and channel decisions China Healthcare Commercial Due Diligencemethodology for assessing market attractiveness and risk Reimbursement Evidence for China Market Accesspayer, hospital, and procurement evidence Data Compliance for Healthcare Companies in ChinaPIPL, localization, cybersecurity, and health data transfer Common Mistakes U.S. Healthcare Companies Make in Chinamyth-versus-fact page focused on market-entry pitfalls

China-to-U.S. market-entry layer

Chinese healthcare companies entering the U.S.

These pages analyze U.S. entry through FDA readiness, reimbursement, CPT and HCPCS coding, coverage, payer evidence, hospital value analysis, distributors, sales teams, KOLs, investor trust, privacy, localization, postmarket support, liability, and common mistakes.

Chinese Healthcare Companies Entering the U.S.canonical China-to-U.S. healthcare market entry playbook Chinese Medtech Companies Entering the U.S.medtech-specific U.S. route from FDA to reimbursement and sales Chinese Biopharma Companies Entering the U.S.biopharma path through FDA, trials, payer evidence, and commercialization FDA Readiness for Chinese Healthcare Companiesregulatory preparedness decision matrix U.S. Reimbursement Readiness for Chinese Companiescoding, coverage, payment, and economic evidence readiness CPT and HCPCS Coding for Chinese Healthcare Companiescode pathways without drowning readers in coding minutiae U.S. Coverage Strategy for Healthcare Productscommercial, Medicare, and Medicaid coverage strategy Payer Evidence for U.S. Market Entryevidence standards for payer and coverage decisions Hospital Value Analysis Committeeshospital adoption gate for devices and supplies U.S. Distributor Strategy for Chinese Medtechchannel design and distributor risk in the U.S. Building a U.S. Sales Organization in Healthcarewhen direct sales makes sense and what it requires U.S. Clinical KOL Strategyclinical credibility-building in U.S. hospitals and specialties U.S. Investor Readiness for Chinese Healthcare Companiesinvestor diligence expectations, trust, and evidence Brand Trust for Chinese Healthcare Companies in the U.S.trust barriers, evidence, service, and geopolitical context U.S. Health Data Privacy for Chinese CompaniesHIPAA and data governance for Chinese entrants Product Localization for the U.S. Healthcare Marketworkflow, evidence, support, documentation, and service localization Postmarket Support in the U.S. Healthcare Marketservice, quality systems, complaints, and adoption durability Product Liability and Litigation Risk in U.S. Healthcarehigh-level risk page for foreign entrants U.S. Reimbursement Pitfalls for Foreign Healthcare Companiesapproval versus payment misunderstandings Common Mistakes Chinese Healthcare Companies Make in the U.S.Chinese-company-specific market-entry pitfalls

Governance and stakeholder layer

China healthcare agencies, laws, professional bodies, and stakeholder map

These pages explain agency roles, implementation authority, data laws, anti-corruption governance, professional regulation, medical education, HTA, and the larger Chinese healthcare stakeholder map.

National Health Commissioncentral health administration and delivery-system policy National Healthcare Security Administration Governance Roleinsurance, payment, procurement, and reimbursement governance National Medical Products Administrationdrug, device, diagnostic, and product regulator Chinese Center for Disease Control and Preventionpublic-health surveillance and disease-control institution Provincial Health Commissions in Chinalocal implementation and regional variation Hospital Associations in Chinaprofessional and institutional association influence Medical Specialty Societies in Chinaclinical norms, KOL networks, and specialty adoption China Academy of Chinese Medical SciencesTCM research and institutional knowledge production Chinese Medical Associationprofessional society and clinical influence National Medical Center Program in Chinacapacity-building and excellence-center policy instrument Healthy China 2030national health strategy and policy direction Basic Medical and Health Promotion Lawlegal framework for basic healthcare and health promotion Data Security Law and Healthcare in Chinadata-security obligations in health context Personal Information Protection Law and HealthcarePIPL implications for health data Cybersecurity Law and Healthcare in Chinanetwork security, critical systems, and healthcare operations Healthcare Anti-Corruption Governance in Chinaagencies, procurement, hospitals, and enforcement logic Physician Licensing in Chinalicensing pathway and professional regulation Medical Education Governance in Chinaeducation ministries, NHC, universities, and hospital training Health Technology Assessment in ChinaHTA as evidence bridge to reimbursement and policy Chinese Healthcare Stakeholder Maptop-level map of ministries, hospitals, insurers, regulators, and companies

Provider market and service-line layer

China provider markets, private care, service lines, and supplemental channels

These pages analyze public hospital reform, private and international care, hospital groups, checkups, rehabilitation, mental health, major service lines, commercial insurance, and employer health benefits.

Public Hospital Reform in Chinagovernance, pricing, compensation, and payment reform Private Hospital Strategy in Chinawhen private hospitals matter and when they do not Premium Private Healthcare in Chinahigh-end care market and demand limits International Hospitals in Chinaforeign-facing and premium private hospital segment United Family Healthcarehistorically important private and international hospital group Hospital Groups in Chinahospital groups, management companies, and health systems Medical Tourism in Chinainbound, outbound, and domestic specialty travel Health Checkup Centers in Chinapreventive screening, employer benefits, and consumer health market Rehabilitation Market in Chinaaging, stroke, post-acute care, and capacity gap Mental Health Market in Chinademand, stigma, workforce, hospitals, and digital platforms Oncology Care Strategy in Chinaservice-line strategy for cancer care, drugs, diagnostics, and hospitals Cardiovascular Care Strategy in Chinacardiovascular disease burden, tertiary hospitals, devices, and pathways Diabetes Care Strategy in Chinachronic care, primary care, devices, drugs, and digital management Ophthalmology Market in Chinaeye-care services, private chains, devices, and elective demand Dental Care Market in Chinaprivate-pay dentistry, implants, orthodontics, and clinic chains Fertility and Reproductive Services in Chinafertility policy, delayed childbearing, ART capacity, and regulation Elderly Care Market in Chinaeldercare services, long-term care insurance, and private participation Insurance Innovation in Chinacommercial insurance, city supplemental plans, and digital insurance Commercial Payer Strategy in Chinahow healthcare companies should think about commercial payers Employer Health Benefits in Chinaemployer health benefits as emerging supplemental channel

Simplified Chinese access layer

中文美国医疗体系与市场进入页面

These simplified Chinese pages explain U.S. healthcare structure, insurance, coding, coverage, reimbursement, FDA/NMPA differences, U.S. commercialization, payer evidence, and common entry mistakes.

中美医疗体系与跨境医疗战略指南选择性入口页 美国医疗体系如何运作美国体系结构说明 美国医保结构多支付方结构 Medicare 是什么Medicare 术语解释 Medicaid 是什么Medicaid 术语解释 美国商业医疗保险商业保险与雇主保险 美国医疗编码、覆盖和报销Coding、Coverage、Reimbursement 三段式 FDA 与 NMPA 的区别FDA 与 NMPA 比较 美国医疗器械商业化路径医疗器械从 FDA 到医院采用 中国医疗器械企业进入美国市场中国器械企业赴美路径 中国生物医药企业进入美国市场中国生物医药赴美路径 美国医疗报销机制支付而非患者报销 美国医院采购机制医院采购、GPO 与价值分析 美国支付方证据要求支付方证据 中国企业进入美国医疗市场的常见误区误区与修正 美国医疗体系常用术语中英对照中英术语入口页 CPT 是什么CPT 编码解释 HCPCS 是什么HCPCS 编码解释 Coverage 和 Reimbursement 的区别覆盖与报销区别 Prior Authorization 是什么事先授权与使用管理

Simplified Chinese reference layer

中文 FAQ、路径图、数据参考、术语表和检查清单

These pages add Chinese-language FAQs, FDA pathway explanations, executive briefs, U.S. cost and insurance data references, payment/regulatory/insurance glossaries, and market-entry checklists.

美国医疗体系常见问题中文读者常见误解 FDA 医疗器械路径图510(k)、De Novo、PMA 路径图 进入美国医疗市场高管简报中国企业美国市场进入摘要 中美医疗体系主要区别面向中文读者的制度差异 美国支付与报销术语表中英支付术语桥 美国监管术语表FDA 术语桥 美国医保术语表美国医保词汇桥 美国医疗成本数据参考美国医疗支出基准 美国医保覆盖数据参考美国保险覆盖结构数据 FDA 批准不等于美国市场成功FDA 之后的商业化门槛 ICD-10 是什么诊断编码 DRG 是什么住院支付分组 PBM 是什么药品福利管理 Value Analysis Committee 是什么医院价值分析委员会 Clinical Evidence 是什么临床证据的多重用途 Real-World Evidence 是什么真实世界证据 CPT Category III 代码是什么新兴技术临时代码 Medicare Coverage 是什么Medicare 覆盖判断 美国医院 Value Analysis 路径图从医生兴趣到采购批准 中国企业美国市场进入检查清单进入美国市场前的准备度评估

Methods and evidence

Sources, evidence standards, and data guides

These pages explain how the site evaluates sources, weighs evidence, uses official data, maintains terminology, supports Chinese-language readers, and preserves historical material.

Sourcessource families and evidence context Evidence Gradingevidence grades used across pages Update Policy Data Sources for China Healthcareannotated guide to Chinese health data sources Data Sources for U.S. Healthcareannotated guide to U.S. health data sources Annotated Bibliography for Healthcare in Chinacore source set for China system pages Annotated Bibliography for Chinese Healthcare Reformsource set for reform pages Annotated Bibliography for Traditional Chinese Medicinesource set for TCM pages Annotated Bibliography for U.S.-China Healthcaresource set for comparison and cross-border pages All Pages Directoryfull human-readable directory Citation Stylesource-note format for static pages Chinese Translation Style Guideterminology and selective translation Chinese Access Layer Policywhy Chinese pages are selective Archive Preservation Policyold conference pages and historical content

Reference guides

Indices, FAQs, agency glossary, and timelines

These pages provide concise entry points into system, hospital, province, insurance, reform, TCM, population health, medtech, biopharma, digital health, market entry, regulatory, Chinese reader, FAQ, agency, and timeline topics.

Health Systems Indexsystem-level pages across U.S., China, and comparisons China Hospitals Directoryhospital architecture and hospital-related pages China Provinces Healthcare Indexprovince and region healthcare profiles China Health Insurance DirectoryChina insurance, financing, reimbursement, and payment pages China Healthcare Reform Directoryreform briefs and policy instruments Traditional Chinese Medicine DirectoryTCM history, regulation, institutions, and debate Population Health in China Indexhealth indicators and disease-burden pages Medtech Indexdevice, diagnostic, procurement, and channel pages Biopharma Indexdrug, trial, supply chain, and licensing pages Digital Health and AI Indexdigital health, AI, data, and cybersecurity pages Market Entry IndexU.S.-to-China and China-to-U.S. strategy pages Regulatory Pathways IndexFDA, NMPA, trial, device, drug, and diagnostic pathway pages U.S. Healthcare for Chinese Readers IndexChinese-language and U.S. system pages for Chinese readers U.S.-China Healthcare FAQtop-level comparison questions China Healthcare FAQChinese healthcare system questions U.S. Market Entry FAQ for Chinese Healthcare CompaniesChina-to-U.S. commercialization Common Mistakes in U.S.-China Healthcare Comparisonsfalse equivalences and generic comparison mistakes Glossary of Chinese Healthcare Agenciesagency-specific glossary and index Timeline of Chinese Healthcare Reformchronological reform spine linking reform pages Timeline of U.S.-China Healthcare Relationshistorical relationship without daily-news framing